AR132408A1 - COMPOUNDS THAT MODULATE KRAS - Google Patents
COMPOUNDS THAT MODULATE KRASInfo
- Publication number
- AR132408A1 AR132408A1 ARP240100920A ARP240100920A AR132408A1 AR 132408 A1 AR132408 A1 AR 132408A1 AR P240100920 A ARP240100920 A AR P240100920A AR P240100920 A ARP240100920 A AR P240100920A AR 132408 A1 AR132408 A1 AR 132408A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- pharmaceutically acceptable
- compounds
- acceptable salt
- kras
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable de este. Una composición farmacéutica que comprende un compuesto de una cualquiera de las reivindicaciones 1 a 69, y un excipiente farmacéuticamente aceptable. Un método para fabricar un medicamento para tratar el cáncer en un sujeto que lo necesita, caracterizado porque se usa un compuesto de una cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este. Un método para fabricar un medicamento para inhibir la metástasis de cáncer en un sujeto que lo necesita, caracterizado porque se usa un compuesto de una cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este.A compound of formula (1), or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a compound of any one of claims 1 to 69, and a pharmaceutically acceptable excipient. A method for manufacturing a medicament for treating cancer in a subject in need thereof, characterized in that a compound of any one of claims 1 to 69, or a pharmaceutically acceptable salt thereof, is used. A method for manufacturing a medicament for inhibiting cancer metastasis in a subject in need thereof, characterized in that a compound of any one of claims 1 to 69, or a pharmaceutically acceptable salt thereof, is used.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063551416P | 2020-02-08 | 2020-02-08 | |
| US202363495497P | 2023-04-11 | 2023-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132408A1 true AR132408A1 (en) | 2025-06-25 |
Family
ID=96172437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100920A AR132408A1 (en) | 2020-02-08 | 2024-04-11 | COMPOUNDS THAT MODULATE KRAS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR132408A1 (en) |
-
2024
- 2024-04-11 AR ARP240100920A patent/AR132408A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129238A1 (en) | CYCLIC COMPOUND THAT HAS SELECTIVE INHIBITORY ACTION ON KRAS ABOVE HRAS AND NRAS | |
| MX2023001689A (en) | BCL-2 INHIBITORS. | |
| CL2021003202A1 (en) | Pyrrolidine compounds | |
| CO2024001367A2 (en) | Antiviral compounds | |
| AR126251A1 (en) | CDK2 INHIBITORS | |
| AR127247A1 (en) | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | |
| MX2024009158A (en) | Parp7 inhibitors. | |
| CO2024006727A2 (en) | Macrocyclic compounds and compositions, and methods for preparing and using the same | |
| AR128932A1 (en) | BCL-XL INHIBITORS | |
| CO2026000093A2 (en) | Pharmaceutical compositions for nek7 kinase inhibitors | |
| AR127496A1 (en) | CD73 COMPOUNDS | |
| MX2019004842A (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety. | |
| AR132408A1 (en) | COMPOUNDS THAT MODULATE KRAS | |
| AR133133A1 (en) | COMPOUNDS THAT MODULATE KRAS | |
| CL2025001119A1 (en) | Cancer treatment methods using isoquinoline or 6-aza-quinoline derivatives | |
| AR133135A1 (en) | COMPOUNDS THAT MODULATE KRAS | |
| AR133755A1 (en) | KRAS G12D MODULATION COMPOUNDS | |
| AR131842A1 (en) | METHODS FOR TREATING GLIOMAS | |
| CL2023000648A1 (en) | Methods for treating diseases or conditions mediated by pde iv | |
| AR129212A1 (en) | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | |
| AR128894A1 (en) | KRAS INHIBITORS | |
| AR128051A1 (en) | PARP1 INHIBITORS | |
| AR125934A1 (en) | MACROCYCLIC COMPOUNDS TO TREAT DISEASES | |
| AR127582A1 (en) | METHODS FOR THE TREATMENT OF CANCER | |
| AR132852A1 (en) | COMBITHERAPY TO TREAT CANCER |